1. Home
  2. GANX vs KOSS Comparison

GANX vs KOSS Comparison

Compare GANX & KOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • KOSS
  • Stock Information
  • Founded
  • GANX 2017
  • KOSS 1953
  • Country
  • GANX United States
  • KOSS United States
  • Employees
  • GANX N/A
  • KOSS N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • KOSS Consumer Electronics/Appliances
  • Sector
  • GANX Health Care
  • KOSS Consumer Staples
  • Exchange
  • GANX Nasdaq
  • KOSS Nasdaq
  • Market Cap
  • GANX 53.4M
  • KOSS 57.5M
  • IPO Year
  • GANX 2021
  • KOSS N/A
  • Fundamental
  • Price
  • GANX $1.92
  • KOSS $6.51
  • Analyst Decision
  • GANX Strong Buy
  • KOSS
  • Analyst Count
  • GANX 5
  • KOSS 0
  • Target Price
  • GANX $8.00
  • KOSS N/A
  • AVG Volume (30 Days)
  • GANX 378.4K
  • KOSS 72.0K
  • Earning Date
  • GANX 08-12-2025
  • KOSS 09-09-2025
  • Dividend Yield
  • GANX N/A
  • KOSS N/A
  • EPS Growth
  • GANX N/A
  • KOSS N/A
  • EPS
  • GANX N/A
  • KOSS N/A
  • Revenue
  • GANX N/A
  • KOSS $12,433,361.00
  • Revenue This Year
  • GANX N/A
  • KOSS N/A
  • Revenue Next Year
  • GANX N/A
  • KOSS N/A
  • P/E Ratio
  • GANX N/A
  • KOSS N/A
  • Revenue Growth
  • GANX N/A
  • KOSS N/A
  • 52 Week Low
  • GANX $0.95
  • KOSS $4.00
  • 52 Week High
  • GANX $3.19
  • KOSS $10.55
  • Technical
  • Relative Strength Index (RSI)
  • GANX 61.71
  • KOSS 64.87
  • Support Level
  • GANX $1.65
  • KOSS $5.30
  • Resistance Level
  • GANX $2.07
  • KOSS $6.60
  • Average True Range (ATR)
  • GANX 0.16
  • KOSS 0.38
  • MACD
  • GANX 0.05
  • KOSS 0.09
  • Stochastic Oscillator
  • GANX 70.15
  • KOSS 75.44

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.

Share on Social Networks: